

EuroValve

October 24-25 2014, Rome, Italy

www.eurovalvecongress.com



Early and mid-term outcomes after aortic valve replacement with a sutureless prosthesis: single center experience.

Carmelo Mignosa¹, Salvatore Di Stefano¹, Carlo Mariani¹, Antonella Romeo¹, Angelo Giuffrida¹, Roberta Adamo², Francesco Monaco², Wanda Deste³, Antonino S Rubino¹

1. Cardiac Surgery Unit, AOU Policlinico-Vittorio Emanuele, Catania, Italy

2. Cardiac Anesthesiology and Intensive Care Unit, AOU Policlinico-Vittorio Emanuele, Catania, Italy


3. Cardiology Unit, AOU Policlinico-Vittorio Emanuele, Catania, Italy

AIM

We evaluated the outcomes of 68 consecutive patients undergone AVR with the sutureless Perceval aortic valve bioprosthesis (Sorin Group, Saluggia, Italy) from April 2011 to June 2014.



Perceval valve




3D rendering of the valve in the aortic box

RESULTS


Preoperative variables

Variables	n=68	Variables	n=68
Age	74.8±5.4 yrs (58-92 yrs)	COPD	16 (23.5%)
Female	45 (66.2%)	EuroSCORE II	5.5±5.3% (1.1%-45.1%)
NYHA(3/4)	58 (85.3%)	EF	56.1±9.1% (25%-76%)
IDDM	19 (27.9%)	Annulus	19.5±6.8 mm (17-26 mm)


Surgical approach




Associated procedures



Aortic cross-clamping time




Hospital outcomes



100% device success

Late survival



100% freedom from valve-related mortality, stroke, redo, endocarditis

CONCLUSIONS

Perceval allows to minimize cross-clamping time and delivers excellent clinical outcome. Furthermore, this valve offers the unique advantage to implant a stentless valve with a sutureless technology, shifting the concept of minimally invasive surgery from small incisions to the minimal manipulation of the heart.